A clinical trial comparing different liver cancer medications (sorafenib, cabozantinib or a combination of cabozantanib and atezolizumab) for treating liver cancer (hepatocellular carcinoma).
About this study
The purpose of this study is to find out if cabozantinib in combination with atezolizumab is effective in treating liver cancer (hepatocellular carcinoma) compared to sorafenib alone in people who have not received prior treatment.
This study will also examine how well people with liver cancer who have not received prior treatment tolerate cabozantinib alone, and how well it works in treating their cancer.
Anticipated enrolment close date: 31 December 2020
Who can take part
Histological or cytological diagnosis of hepatocellular carcinoma
Prior anticancer therapy
- Medical history
- Physical exam
- Blood pressure
- Heart rate
- Health questionnaires
- Liver biopsy (optional)
- Blood samples
- Urine test
- Abdominal scan
All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.
This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.
The Clinical Trials Centre (CTC) is a dedicated, purpose-built space where we conduct clinical trials.
The CTC is located on Level 2 South. When you arrive, if you are unsure where to go, talk to one of our friendly volunteers or the information desk staff.